Stoke Therapeutics (NASDAQ:STOK) CFO Thomas Leggett Sells 2,196 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CFO Thomas Leggett sold 2,196 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total value of $72,489.96. Following the completion of the transaction, the chief financial officer directly owned 12,554 shares in the company, valued at approximately $414,407.54. This represents a 14.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Thomas Leggett also recently made the following trade(s):

• On Wednesday, March 18th, Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total value of $74,651.88.

Stoke Therapeutics Stock Up 3.7%

NASDAQ STOK opened at $34.41 on Friday. The company has a 50-day moving average price of $32.60 and a 200-day moving average price of $29.93. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $40.22. The firm has a market capitalization of $2.04 billion, a P/E ratio of 51.46 and a beta of 1.07.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its stake in Stoke Therapeutics by 333.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after purchasing an additional 1,116,452 shares during the period. State Street Corp raised its position in shares of Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after buying an additional 1,072,176 shares during the last quarter. Corient Private Wealth LLC bought a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $7,489,000. BVF Inc. IL lifted its holdings in shares of Stoke Therapeutics by 36.7% in the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after buying an additional 608,578 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Stoke Therapeutics by 438.2% in the third quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after buying an additional 600,687 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. HC Wainwright increased their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday, December 15th. Loop Capital set a $35.00 price objective on Stoke Therapeutics in a research note on Monday, January 5th. Wolfe Research assumed coverage on Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Needham & Company LLC lifted their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.